Stockreport

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Ag...

Ocugen, Inc.  (OCGN) 
PDF Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profi [Read more]